CASI Pharmaceuticals Secures $15M in Funding
Company Announcements

CASI Pharmaceuticals Secures $15M in Funding

CASI Pharmaceuticals (CASI) has released an update.

CASI Pharmaceuticals has announced a $15 million private placement financing led by prominent investors, aiming to advance its development of innovative therapeutics. The financing involves the sale of 1,020,000 ordinary shares and pre-funded warrants, underlining investor confidence in the company’s strategic direction and mission. The deal, which is set to close in mid-July 2024, highlights CASI’s commitment to becoming a leader in the pharmaceutical industry, particularly in the hematology oncology sector.

For further insights into CASI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyCasi Pharmaceuticals receives CTA approval from China NMPA for CID-103
TipRanks Auto-Generated NewsdeskCASI Pharmaceuticals Revamps Management Structure
TheFlyCasi Pharmaceuticals files to sell 3M ordinary shares for holders
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App